However, prolonged treatment with these drugs reduces the ROS content in cancer cells, inducing resistance to chemotherapeutic agents [57] through adaptive mechanisms regulated by the Nrf2/ARE axis [11]. The gene discussed is NFE2L2; the disease is cancer.